調查批次:CHT2017-04 | 檢體寄出日期:2017-09-25 | 報告回收截止日期:2017-10-02 | 回收份數:22 |
T4 檢驗院際品管調查結果: | ||
2.歷次品管檢體 T4 檢驗值之實驗室間 CV 分佈圖 | ||
4.至本次各單位 z score 分佈圖 | 5.至本次各單位 D% 分佈圖 | 6.至本次各單位 SDI 分佈圖 |
檢驗單位 <代碼> |
確診醫院 <代碼> |
回報 天數 |
檢體 S1 |
檢體 S2 |
||||||||||||
( µg/dL ) |
D |
D% |
z |
SDI |
Da% |
( µg/dL ) |
D |
D% |
z |
SDI |
Da% |
|||||
RH01b | RH01 | 1 |
2 |
5 |
13.9 |
-3.0 |
-17.8 |
-2.2 |
-0.2 |
-74 |
6.8 |
-1.2 |
-15.0 |
-1.9 |
-0.5 |
-63 |
RH07b | RH07 | 4 |
2 |
3 |
14.4 |
-2.5 |
-14.8 |
-1.8 |
0.1 |
-62 |
6.9 |
-1.1 |
-13.8 |
-1.7 |
-0.4 |
-57 |
RH15 | RH15 | 4 |
2 |
6 |
26.4 |
9.5 |
56.2 |
7.0 |
6.6 |
234 |
14.9 |
6.9 |
86.3 |
10.8 |
10.0 |
359 |
CL009 | CL009 | 4 |
2 |
5 |
13.2 |
-3.7 |
-21.9 |
-2.7 |
-0.6 |
-91 |
6.9 |
-1.1 |
-13.8 |
-1.7 |
-0.4 |
-57 |
CL010 | CL010 | 4 |
2 |
5 |
15.8 |
-1.1 |
-6.5 |
-0.8 |
0.8 |
-27 |
7.9 |
-0.1 |
-1.3 |
-0.2 |
0.9 |
-5 |
CL012 | CL012 | 7 |
2 |
3 |
12.4 |
-4.5 |
-26.6 |
-3.3 |
-1.0 |
-111 |
7.3 |
-0.7 |
-8.8 |
-1.1 |
0.1 |
-36 |
CL014a | CL014 | 4 |
2 |
5 |
13.3 |
-3.6 |
-21.3 |
-2.7 |
-0.5 |
-89 |
6.5 |
-1.5 |
-18.8 |
-2.3 |
-0.9 |
-78 |
Median of RIA Group |
13.9 |
6.9 |
||||||||||||||
Range of RIA Group |
12.4 - 26.4 |
6.5 - 14.9 |
||||||||||||||
Robust mean of RIA Group |
14.3 ( n = 7 ) |
7.2 ( n = 7 ) |
||||||||||||||
Robust SD of RIA Group |
1.84 |
0.77 |
||||||||||||||
CV of RIA Group |
12.9% |
10.7% |
||||||||||||||
檢驗單位 <代碼> |
確診醫院 <代碼> |
回報 天數 |
檢體 S1 |
檢體 S2 |
||||||||||||
( µg/dL ) |
D |
D% |
z |
SDI |
Da% |
( µg/dL ) |
D |
D% |
z |
SDI |
Da% |
|||||
RH01a | RH01 | 7 |
4 |
9 |
16.5 |
-0.4 |
-2.4 |
-0.3 |
0.7 |
-10 |
8.1 |
0.1 |
1.3 |
0.2 |
1.3 |
5 |
RH02c | RH02 | 3 |
4 |
1 |
16.8 |
-0.1 |
-0.6 |
-0.1 |
1.0 |
-2 |
6.7 |
-1.3 |
-16.3 |
-2.0 |
-1.3 |
-68 |
RH06 | RH06 | 7 |
4 |
9 |
16.5 |
-0.4 |
-2.4 |
-0.3 |
0.7 |
-10 |
7.1 |
-0.9 |
-11.3 |
-1.4 |
-0.6 |
-47 |
RH07a | RH07 | 7 |
4 |
2 |
15.0 |
-1.9 |
-11.2 |
-1.4 |
-0.7 |
-47 |
7.1 |
-0.9 |
-11.3 |
-1.4 |
-0.6 |
-47 |
RH12 | RH12 | 3 |
4 |
2 |
13.8 |
-3.1 |
-18.3 |
-2.3 |
-1.8 |
-76 |
7.3 |
-0.7 |
-8.8 |
-1.1 |
-0.2 |
-36 |
RH14 | RH14 | 4 |
4 |
14 |
16.5 |
-0.4 |
-2.4 |
-0.3 |
0.7 |
-10 |
7.7 |
-0.3 |
-3.8 |
-0.5 |
0.6 |
-16 |
RH15b | RH15b | 4 |
4 |
13 |
15.3 |
-1.6 |
-9.5 |
-1.2 |
-0.4 |
-39 |
7.8 |
-0.2 |
-2.5 |
-0.3 |
0.8 |
-10 |
RH19 | RH19 | 7 |
4 |
2 |
15.2 |
-1.7 |
-10.1 |
-1.3 |
-0.5 |
-42 |
7.6 |
-0.4 |
-5.0 |
-0.6 |
0.4 |
-21 |
RH20 | RH20 | 8 |
4 |
7 |
17.2 |
0.3 |
1.8 |
0.2 |
1.4 |
7 |
7.9 |
-0.1 |
-1.3 |
-0.2 |
1.0 |
-5 |
CL005 | CL005 | 7 |
4 |
9 |
16.2 |
-0.7 |
-4.1 |
-0.5 |
0.5 |
-17 |
7.8 |
-0.2 |
-2.5 |
-0.3 |
0.8 |
-10 |
CL006a | CL006 | 4 |
4 |
7 |
16.0 |
-0.9 |
-5.3 |
-0.7 |
0.3 |
-22 |
8.0 |
0.0 |
0.0 |
0.0 |
1.2 |
0 |
CL008 | CL008 | 7 |
4 |
2 |
14.5 |
-2.4 |
-14.2 |
-1.8 |
-1.1 |
-59 |
7.2 |
-0.8 |
-10.0 |
-1.3 |
-0.4 |
-42 |
CL011 | CL011 | 0 |
4 |
13 |
14.4 |
-2.5 |
-14.8 |
-1.8 |
-1.2 |
-62 |
7.1 |
-0.9 |
-11.3 |
-1.4 |
-0.6 |
-47 |
CL013b | CL013b | 2 |
4 |
1 |
15.4 |
-1.5 |
-8.9 |
-1.1 |
-0.3 |
-37 |
5.8 |
-2.2 |
-27.5 |
-3.4 |
-3.1 |
-115 |
CL015b | CL015b | 3 |
4 |
7 |
16.0 |
-0.9 |
-5.3 |
-0.7 |
0.3 |
-22 |
7.5 |
-0.5 |
-6.3 |
-0.8 |
0.2 |
-26 |
Median of CLIA Group |
16.0 |
7.5 |
||||||||||||||
Range of CLIA Group |
13.8 - 17.2 |
5.8 - 8.1 |
||||||||||||||
Robust mean of CLIA Group |
15.7 ( n = 15 ) |
7.4 ( n = 15 ) |
||||||||||||||
Robust SD of CLIA Group |
1.07 |
0.52 |
||||||||||||||
CV of CLIA Group |
6.8% |
7.0% |
||||||||||||||
Median of All Labs |
15.4 |
7.3 |
||||||||||||||
Range of All Labs |
12.4 - 26.4 |
5.8 - 14.9 |
||||||||||||||
Robust mean of All Labs |
15.3 ( n = 22 ) |
7.4 ( n = 22 ) |
||||||||||||||
Robust SD of All Labs |
1.52 |
0.60 |
||||||||||||||
CV of All Labs |
9.9% |
8.1%
|
||||||||||||||
Certified assigned value ( Xa )( µg/dL ) |
16.9 |
8.0 |
||||||||||||||
Expanded uncertainty ( Ua ) |
0.171 |
0.085 |
||||||||||||||
Relative expanded uncertainty |
1.0% |
1.1% |
||||||||||||||
Coverage factor k |
2.6 |
2.6 |
||||||||||||||
Effective degrees of freedom veff |
5 |
5 |
||||||||||||||
SD for proficiency assessment ( σp ) |
1.352 |
0.640 |
||||||||||||||
Adjusted SD for proficiency assessment ( σp ' ) |
- |
- |
||||||||||||||
|
Method Code
|
Laboratory |
|
Radioimmunoassay ( Competitive-type ) |
2 |
RH01b, RH07b, RH15, CL009, CL010, CL012, CL014a, |
Chemiluminescent Immunoassay ( Competitive-type ) |
4 |
RH01a, RH02c, RH06, RH07a, RH12, RH14, RH15b, RH19, RH20, CL005, CL006a, CL008, CL011, CL013b, CL015b, |
Reagent Code |
Laboratory |
|
Abbott Architect |
1 |
RH02c, CL013b, |
Beckman Coulter Access |
2 |
RH07a, RH12, RH19, CL008, |
Cisbio RIA-gnost |
3 |
RH07b, CL012, |
Immunotech |
5 |
RH01b, CL009, CL010, CL014a, |
MP |
6 |
RH15, |
Siemens ADVIA Centaur |
7 |
RH20, CL006a, CL015b, |
Siemens Immulite 2000 |
9 |
RH01a, RH06, CL005, |
Roche |
13 |
RH15b, CL011, |
Johnson & Johnson ortho vitros |
14 |
RH14, |
若有任何疑問,歡迎來電(函)聯繫或指教
財團法人預防醫學基金會
地 址:10699 臺北信維郵局第 624 信箱 電 話:(02)
2703-6080
e-mail:
傳 真: (02)
2703-6070
updated
: 2017-10-05